| Dennis Wayne Crabb, MD | |
|
115 N 14th St, Denison, IA 51442-1452 | |
| (712) 263-5071 | |
| (712) 263-6106 |
| Full Name | Dennis Wayne Crabb |
|---|---|
| Gender | Male |
| Speciality | Surgery |
| Location | 115 N 14th St, Denison, Iowa |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760453302 | NPI | - | NPPES |
| 18961 | Other | IA | LICENSE NUMBER |
| 0141002 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 18961 (Iowa) | Primary |
| 208D00000X | General Practice | 18961 (Iowa) | Secondary |
| Entity Name | Crawford County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619969086 PECOS PAC ID: 7810890555 Enrollment ID: O20040129000821 |
News Archive
Researchers at the Imperial College's South Kensington campus have successfully created genetically modified mosquitoes that would stop them from multiplying and spreading dreaded diseases such as malaria, Dengue, Chikungunya and Zika that kill millions worldwide annually.
New clinical data on a range of innovative medical devices from Medtronic, Inc., to treat cardiac and vascular diseases - from severe aortic stenosis and uncontrolled hypertension, to coronary and peripheral artery disease - will be presented next week at EuroPCR. Many of the presentations will be featured during late-breaking sessions at this large international interventional cardiology meeting, which takes place in Paris from May 17-20.
In our guts, and in the guts of all animals, resides a robust ecosystem of microbes known as the microbiome. Consisting of trillions of organisms — bacteria, fungi and viruses — the microbiome is essential for host health, providing important services ranging from nutrient processing to immune system development and maintenance.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.
The Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria on Monday will award nine companies for their efforts to fight the three diseases among employees, South Africa's Business Day reports. The coalition is a group of 220 companies worldwide that aim to address HIV, TB and malaria in the workplace.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dennis Wayne Crabb, MD 115 N 14th St, Denison, IA 51442-1452 Ph: (712) 263-5071 | Dennis Wayne Crabb, MD 115 N 14th St, Denison, IA 51442-1452 Ph: (712) 263-5071 |
News Archive
Researchers at the Imperial College's South Kensington campus have successfully created genetically modified mosquitoes that would stop them from multiplying and spreading dreaded diseases such as malaria, Dengue, Chikungunya and Zika that kill millions worldwide annually.
New clinical data on a range of innovative medical devices from Medtronic, Inc., to treat cardiac and vascular diseases - from severe aortic stenosis and uncontrolled hypertension, to coronary and peripheral artery disease - will be presented next week at EuroPCR. Many of the presentations will be featured during late-breaking sessions at this large international interventional cardiology meeting, which takes place in Paris from May 17-20.
In our guts, and in the guts of all animals, resides a robust ecosystem of microbes known as the microbiome. Consisting of trillions of organisms — bacteria, fungi and viruses — the microbiome is essential for host health, providing important services ranging from nutrient processing to immune system development and maintenance.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.
The Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria on Monday will award nine companies for their efforts to fight the three diseases among employees, South Africa's Business Day reports. The coalition is a group of 220 companies worldwide that aim to address HIV, TB and malaria in the workplace.
› Verified 9 days ago
David J. Wright, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Medical Pkwy, Suite A, Denison, IA 51442 Phone: 712-265-2700 Fax: 712-265-2745 |